Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00831012 · ClinicalTrials.gov registry record · Phase 1
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31-7164) in Healthy Adults
A Phase 1 study of Dengue Fever, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT00831012 is a Phase 1 study of Dengue Fever that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 56 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00831012, a Phase 1 study of Dengue Fever, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
Dengue fever, which is caused by dengue viruses, is a major health problem in tropical and subtropical regions of the world. The purpose of this study is to test the safety of and immune response to a new dengue virus vaccine in healthy adults.
Conditions Studied
Interventions
- BIOLOGICAL rDEN3delta30/31-7164
Study Locations (1)
Maryland
- Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2009-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00831012
The ClinicalTrials.gov registry entry for NCT00831012 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dengue Fever appearing as the primary indexed condition, and to 1 intervention - of which rDEN3delta30/31-7164 is the first listed.
NCT00831012 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00831012 about?
NCT00831012 is a clinical study titled "Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31-7164) in Healthy Adults". Dengue fever, which is caused by dengue viruses, is a major health problem in tropical and subtropical regions of the world. The purpose of this study is to test the safety of and immune response to a new dengue virus vaccine in healthy adults.
What is the current status of trial NCT00831012?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2009-09.
What conditions does trial NCT00831012 study?
This clinical trial studies the following conditions: Dengue Fever.
What interventions are being tested in trial NCT00831012?
The interventions under investigation include: rDEN3delta30/31-7164 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00831012?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00831012 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dengue Fever
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.